Viking Therapeutics (VKTX) Retained Earnings (2014 - 2026)

Viking Therapeutics has disclosed Retained Earnings across 13 years of filings, most recently posting -$1.0 billion for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$1.0 billion, down 88.53% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.0 billion (down 88.53% YoY), and the FY2025 annual result was -$847.5 million, down 73.71% from the prior year.
• Retained Earnings came in at -$1.0 billion for Q1 2026 at Viking Therapeutics, down from -$847.5 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$239.3 million in Q1 2022 to a low of -$1.0 billion in Q1 2026.
• The 5-year median for Retained Earnings is -$405.3 million (2024), against an average of -$463.7 million.
• Across the five-year window, Retained Earnings fell 28.06% in 2024 and sank 88.53% in 2026, its largest moves.
• Viking Therapeutics' Retained Earnings stood at -$292.0 million in 2022, then slipped by 29.41% to -$377.9 million in 2023, then declined by 29.1% to -$487.9 million in 2024, then slumped by 73.71% to -$847.5 million in 2025, then slipped by 18.68% to -$1.0 billion in 2026.
• The last three Retained Earnings figures came in at -$1.0 billion (Q1 2026), -$847.5 million (Q4 2025), and -$689.9 million (Q3 2025), per Business Quant data.